Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines

被引:54
作者
Rubner, Yvonne [1 ]
Muth, Carolin [1 ]
Strnad, Annedore [1 ]
Derer, Anja [1 ]
Sieber, Renate [1 ]
Buslei, Rolf [2 ]
Frey, Benjamin [1 ]
Fietkau, Rainer [1 ]
Gaipl, Udo S. [1 ]
机构
[1] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Radiat Oncol, D-91054 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Neuropathol, D-91054 Erlangen, Germany
关键词
Glioblastoma multiforme; Fractionated radiotherapy; Temozolomide; Valproic acid; Clonogenic potential; G2 cell cycle arrest; Apoptosis; Necrosis; Hsp70; Immunogenic cell death; HUMAN TUMOR-CELLS; VALPROIC ACID USE; GLIOMA-CELLS; IONIZING IRRADIATION; DENDRITIC CELLS; ADJUVANT TEMOZOLOMIDE; HISTONE DEACETYLASE; IMMUNE-RESPONSES; IN-VITRO; RADIATION;
D O I
10.1186/1748-717X-9-89
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Despite a multimodal therapy consisting of resection followed by fractionated radiotherapy (RT) combined with the chemotherapeutic agent (CT) temozolomide (TMZ), its recurrence is almost inevitable. Since the immune system is capable of eliminating small tumor masses, a therapy should also aim to stimulate anti-tumor immune responses by induction of immunogenic cell death forms. The histone deacetylase inhibitor valproic acid (VPA) might foster this. Methods: Reflecting therapy standards, we applied in our in vitro model fractionated RT with a single dose of 2Gy and clinically relevant concentrations of CT. Not only the impact of RT and/or CT with TMZ and/or VPA on the clonogenic potential and cell cycle of the glioblastoma cell lines T98G, U251MG, and U87MG was analyzed, but also the resulting cell death forms and release of danger signals such as heat-shock protein70 (Hsp70) and high-mobility group protein B1 (HMGB1). Results: The clonogenic assays revealed that T98G and U251MG, having mutated tumor suppressor protein p53, are more resistant to RT and CT than U87MG with wild type (WT) p53. In all glioblastoma cells lines, fractionated RT induced a G2 cell cycle arrest, but only in the case of U87MG, TMZ and/or VPA alone resulted in this cell cycle block. Further, fractionated RT significantly increased the number of apoptotic and necrotic tumor cells in all three cell lines. However, only in U87MG, the treatment with TMZ and/or VPA alone, or in combination with fractionated RT, induced significantly more cell death compared to untreated or irradiated controls. While necrotic glioblastoma cells were present after VPA, TMZ especially led to significantly increased amounts of U87MG cells in the radiosensitive G2 cell cycle phase. While CT did not impact on the release of Hsp70, fractionated RT resulted in significantly increased extracellular concentrations of Hsp70 in p53 mutated and WT glioblastoma cells. Conclusions: Our results indicate that fractionated RT is the main stimulus for induction of glioblastoma cell death forms with immunogenic potential. The generated tumor cell microenvironment might be beneficial to include immune therapies for GBM in the future.
引用
收藏
页数:15
相关论文
共 86 条
[1]   P53-PROTEIN ACCUMULATION AND GENE-MUTATIONS IN HUMAN GLIOMA CELL-LINES [J].
ANKER, L ;
OHGAKI, H ;
LUDEKE, BI ;
HERRMANN, HD ;
KLEIHUES, P ;
WESTPHAL, M .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (06) :982-987
[2]   Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial [J].
Ardon, Hilko ;
Van Gool, Stefaan W. ;
Verschuere, Tina ;
Maes, Wim ;
Fieuws, Steffen ;
Sciot, Raf ;
Wilms, Guido ;
Demaerel, Philippe ;
Goffin, Jan ;
Van Calenbergh, Frank ;
Menten, Johan ;
Clement, Paul ;
Debiec-Rychter, Maria ;
De Vleeschouwer, Steven .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (11) :2033-2044
[3]   Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study [J].
Ardon, Hilko ;
Van Gool, Stefaan ;
Lopes, Isabel Spencer ;
Maes, Wim ;
Sciot, Raf ;
Wilms, Guido ;
Demaerel, Philippe ;
Bijttebier, Patricia ;
Claes, Laurence ;
Goffin, Jan ;
Van Calenbergh, Frank ;
De Vleeschouwer, Steven .
JOURNAL OF NEURO-ONCOLOGY, 2010, 99 (02) :261-272
[4]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[5]   Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival [J].
Barker, Christopher A. ;
Bishop, Andrew J. ;
Chang, Maria ;
Beal, Kathryn ;
Chan, Timothy A. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (03) :504-509
[6]   Temozolomide preferentially depletes cancer stem cells in glioblastoma [J].
Beier, Dagmar ;
Roehrl, Stefanie ;
Pillai, Deepu R. ;
Schwarz, Stefanie ;
Kunz-Schughart, Leoni A. ;
Leukel, Petra ;
Proescholdt, Martin ;
Brawanski, Alexander ;
Bogdahn, Ulrich ;
Trampe-Kieslich, Ariane ;
Giebel, Bernd ;
Wischhusen, Joerg ;
Reifenberger, Guido ;
Hau, Peter ;
Beier, Christoph P. .
CANCER RESEARCH, 2008, 68 (14) :5706-5715
[7]   O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells [J].
Blough, Michael D. ;
Zlatescu, Magdalena C. ;
Cairncross, J. Gregory .
CANCER RESEARCH, 2007, 67 (02) :580-584
[8]  
Blumenthal DT, 2006, J CLIN ONCOL, V24, p61S
[9]   Heterogeneity Maintenance in Glioblastoma: A Social Network [J].
Bonavia, Rudy ;
Inda, Maria-del-Mar ;
Cavenee, Webster K. ;
Furnari, Frank B. .
CANCER RESEARCH, 2011, 71 (12) :4055-4060
[10]   Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies [J].
Brada, M ;
Judson, I ;
Beale, P ;
Moore, S ;
Reidenberg, P ;
Statkevich, P ;
Dugan, M ;
Batra, V ;
Cutler, D .
BRITISH JOURNAL OF CANCER, 1999, 81 (06) :1022-1030